Explore
Settings

Settings

×

Reading Mode

Adjust the reading mode to suit your reading needs.

Font Size

Fix the font size to suit your reading preferences

Language

Select the language of your choice. NewsX reports are available in 11 global languages.
we-woman
Advertisement

Vivek Ramaswamy’s Net Worth: A Young Billionaire Championing Capitalism and Efficiency

At the young age of 39, Trump's newly created Department of Government Efficiency (DOGE) co-director and a billionaire, Vivek Ramaswamy, is a strong proponent of what he calls "excellence capitalism" to unify America.

Vivek Ramaswamy’s Net Worth: A Young Billionaire Championing Capitalism and Efficiency

At the young age of 39, Trump’s newly created Department of Government Efficiency (DOGE) co-director and a billionaire, Vivek Ramaswamy, is a strong proponent of what he calls “excellence capitalism” to unify America. Dubbed as a self-made billionaire, Ramaswamy’s wealth primarily derives from biotech ventures and a wide array of investments in technology, cryptocurrency, and asset management. A Harvard and Yale Law graduate, Ramaswamy was born into the U.S. to Indian immigrant parents, and it was in 2023 when he came to prominence after declaring his candidacy for the Republican Party nomination.

Billionaire Tycoon Rich with Biotech Wealth

Ramaswamy’s net worth, more than over $1 billion, is mainly drawn from Roivant Sciences, the biotech firm he founded in 2014. He has been buying and developing underappreciated pharmaceutical assets and advancing them through the commercialization stages. In 2016, he launched Myovant Sciences, a subsidiary of Roivant, raising the largest biotech IPO of the year, by selling $218 million through listing on Nasdaq.

The most transformative financial moment for Roivant—and Ramaswamy’s personal wealth—came in 2020, when Japanese firm Sumitomo Dainippon acquired a portfolio of five Roivant drugs, plus a 10% company stake, for $3 billion. Ramaswamy was likely to take home capital gains of around $176 million. By 2021, Roivant’s valuation stood at $7.3 billion following a merger via a Special Purpose Acquisition Company, or SPAC. Ramaswamy’s own 7% stake was now valued at around $511 million.

Expanding influence through diversified investments

Beyond biotech, Ramaswamy diversified his portfolio by investing in quite a gamut of sectors. Stocks, bonds, and even developing technologies such as cryptocurrencies hold pieces of his wealth. He also has stakes in some digital platforms, such as Rumble against YouTube and MoonPay, a firm which is a pioneer in crypto payments. It all points to the confidence he bears for the growth story in digital technology and finance, which enhances his wealth and influence all the more.

Political Aspirations and “Excellence Capitalism”

Ramaswamy started his political career in 2021 with the book Woke, Inc. where he took shots at corporate America for focusing too much on social issues. Next, he launched Strive Asset Management, an anti-woke investment firm that is valued around $300 million and is backed by prominent venture capital investors like Peter Thiel and Bill Ackman. Ramaswamy’s excellent capitalism philosophy encourages companies to focus on delivering exceptional value to customers rather than any social or political objectives. His model shows him drawing against the approach of stakeholder capitalism and advocates the customer-centered business practices, and driving economic and societal advancement.

Read More : Brazil Horror: 38-Year-Old Woman Strangled To Death After Refusing To Kiss Her Coworker

mail logo

Subscribe to receive the day's headlines from NewsX straight in your inbox